Clinical Research Directory

Inclusion Criteria: * Patients 18 years or older. * Signature of the form consent for participation in the study. * Diagnosis of APL (either primary or secondary) according to the criteria of the World Health Organization (WHO), without prior treatment. * Identification of the specific genetic alteration of APL by conventional karyotype, fluorescent in situ hybridization (FISH), reverse transcriptase polymerase chain reaction (RT-PCR or RQ-PCR). Identification of the transcript is recommended at the time of diagnosis isoforms: bcr1, bcr2, bcr3 essential to document the therapeutic response: Molecular remission Exclusion Criteria: * Presence of other concomitant active malignant tumors that require simultaneous treatment. * Having received prior treatment for APL. * Electrocardiogram abnormalities: 1. Patients with a pre-existing diagnosis of Long QT Syndrome 2. Patients with a baseline QTc of\> 450msec. The Bazett formula should be used to measure the corrected QT interval (QT interval in msec divided by the square root of the RR interval in msec). 3. Patients with a history or presence of significant ventricular or atrial tachyarrhythmia (Grade 3-4, CTCAE v5.2017). 4. Patients with right bundle branch block plus left anterior hemiblock. Bifascicular blocks are excluded. * ECOG score 4. * Stage III-IV heart failure. * Serum creatinine ≥ 2.5 mg / dL (≥ 250 μmol / L) unless due to APL. * Bilirubin ≥ 2.5 mg / dL, alkaline phosphatase, GPT or GOT\> 3 times the normal limit unless it is for APL. * Severe psychiatric illness. * Women who are pregnant or who have decided to continue breastfeeding.